Billions Lack Access to Life-Saving Drugs. Can AI Be the Game-Changer?
For decades, a cruel irony has plagued global healthcare: as technology advances exponentially, the cost of developing life-saving drugs skyrockets. This phenomenon, known as Eroom’s Law, has left billions in the Global South stranded, unable to afford critical treatments. But here’s where it gets exciting: artificial intelligence (AI) is poised to disrupt this devastating trend, offering a glimmer of hope for a healthier future.
Imagine slashing the time and cost of drug development by leaps and bounds. That’s the promise of AI. Traditionally, bringing a single drug to market takes over a decade and costs upwards of $2 billion, with a staggering 90% failure rate. For developing nations, these numbers are simply insurmountable. AI steps in as a game-changer by supercharging the “pre-clinical stage,” where researchers sift through millions of compounds to find potential drug candidates. Tools like AlphaFold 3, which can predict molecular structures in mere hours, are revolutionizing this process, replacing months of trial and error.
And this is the part most people miss: the impact is already tangible. An AI startup recently identified a new drug target and designed a molecule for human trials in just 18 months, at a cost of $2.7 million – a fraction of the usual expense. For countries like Bangladesh, with its thriving pharmaceutical sector, this opens doors to shift from generic manufacturing to cutting-edge innovation. If AI can double R&D productivity, the cost of medicine could plummet, making healthcare accessible to millions more in Africa and Asia.
But AI’s potential extends far beyond pills. Controversially, some argue that AI-powered cancer vaccines could be the next frontier. In 2025, mRNA-based personalized vaccines, tailored to individual tumor mutations, made headlines. While currently expensive, efforts are underway to develop “off-the-shelf” versions targeting common markers, offering a more affordable solution for developing nations grappling with rising non-communicable diseases.
However, this AI-driven utopia faces significant hurdles. The elephant in the room? Infrastructure. AI isn’t magic; it requires massive data centers, or “AI factories,” guzzling energy at an alarming rate. The International Energy Agency predicts data center power consumption will double by 2026, reaching levels comparable to Japan’s total electricity use. For developing nations already struggling with unreliable grids and debt, powering this technology could be a Catch-22.
Adding to the complexity is the Sino-American tech war. The AI revolution relies on high-powered semiconductors, like Nvidia’s Blackwell chip. As the US restricts technology flow to China, developing nations risk getting caught in the crossfire, unable to access the hardware needed for advanced medical AI.
Yet, there’s a silver lining. Emerging markets are projected to outpace developed nations in growth, even as the latter face a productivity slump. Countries like China and India are already innovating within constraints, proving that resourcefulness can overcome limitations. Why not establish “global capability centers” for AI-driven diagnostics and drug screening in these regions?
To truly harness AI’s potential, developing nations must move beyond being passive consumers of Western technology. They need to embrace selective openness, attract top talent, and invest in green energy infrastructure to power the AI factories of tomorrow.
2026 is shaping up to be a pivotal year, testing the gap between AI hype and reality. If we can navigate geopolitical tensions and infrastructure challenges, AI could be the key to unlocking affordable healthcare for the Global South, bypassing the high-cost barriers of the past century. It’s time to ensure that the “AI factory” doesn’t just generate wealth for Silicon Valley, but health for the world.
What do you think? Can AI truly democratize healthcare, or will infrastructure and geopolitical hurdles prove insurmountable? Share your thoughts in the comments below.
Benzir Ahammed Shawon is a graduate student in applied mathematics and computational science at North South University. Contact him at [email protected]. Views expressed are the author's own.
Follow The Daily Star Opinion on Facebook for more insightful analyses. Interested in contributing? Check out our submission guidelines.
